Marcel B Bally

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3350591/publications.pdf

Version: 2024-02-01

182	11,105	25034	36028
papers	citations	57 h-index	97 g-index

183	183	183	12233
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Monolignol export by diffusion down a polymerization-induced concentration gradient. Plant Cell, 2022, 34, 2080-2095.	6.6	30
2	DMPC/Chol liposomal copper CX5461 is therapeutically superior to a DSPC/Chol formulation. Journal of Controlled Release, 2022, 345, 75-90.	9.9	4
3	Development and characterization of a novel flavopiridol formulation for treatment of acute myeloid leukemia. Journal of Controlled Release, 2021, 333, 246-257.	9.9	15
4	Characterization of a liposomal copper(II)-quercetin formulation suitable for parenteral use. Drug Delivery and Translational Research, 2020, 10, 202-215.	5.8	22
5	Liposomal OTS964, a TOPK inhibitor: a simple method to estimate OTS964 association with liposomes that relies on enhanced OTS964 fluorescence when bound to albumin. Drug Delivery and Translational Research, 2019, 9, 1082-1094.	5.8	4
6	Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia. Pharmaceutical Research, 2019, 36, 125.	3.5	46
7	What Drives Innovation: The Canadian Touch on Liposomal Therapeutics. Pharmaceutics, 2019, 11, 124.	4.5	19
8	Transition Metal Ions Promote the Bioavailability of Hydrophobic Therapeutics: Cu and Zn Interactions with RNA Polymeraseâ€...I Inhibitor CX5461. Chemistry - A European Journal, 2018, 24, 6334-6338.	3.3	6
9	Development of a copper-clioquinol formulation suitable for intravenous use. Drug Delivery and Translational Research, 2018, 8, 239-251.	5.8	26
10	Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response. International Journal of Molecular Sciences, 2018, 19, 2922.	4.1	30
11	Copper-CX-5461: A novel liposomal formulation for a small molecule rRNA synthesis inhibitor. Journal of Controlled Release, 2018, 286, 1-9.	9.9	11
12	Developing liposomal nanomedicines for treatment of patients with neuroblastoma. , 2018, , 361-411.		3
13	CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours. Nature Communications, 2017, 8, 14432.	12.8	379
14	In vitro assay for measuring real time topotecan release from liposomes: release kinetics and cellular internalization. Drug Delivery and Translational Research, 2017, 7, 544-557.	5.8	7
15	Optimization of liposomal topotecan for use in treating neuroblastoma. Cancer Medicine, 2017, 6, 1240-1254.	2.8	19
16	A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer. Journal of Controlled Release, 2017, 252, 50-61.	9.9	33
17	Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status. Investigational New Drugs, 2017, 35, 682-690.	2.6	27
18	In Vivo Validation of PAPSS1 (3â€²-phosphoadenosine 5â€²-phosphosulfate synthase 1) as a Cisplatin-sensitizing Therapeutic Target. Clinical Cancer Research, 2017, 23, 6555-6566.	7.0	12

#	Article	IF	Citations
19	A Perspective â€“ can copper complexes be developed as a novel class of therapeutics?. Dalton Transactions, 2017, 46, 10758-10773.	3.3	140
20	Unique therapeutic properties and preparation methodology of multivalent rituximab-lipid nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 117, 256-269.	4.3	4
21	Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent. International Journal of Nanomedicine, 2017, Volume 12, 4129-4146.	6.7	52
22	Sulfonation, an underexploited area: from skeletal development to infectious diseases and cancer. Oncotarget, 2016, 7, 55811-55827.	1.8	34
23	Nanoscale Reaction Vessels Designed for Synthesis of Copper-Drug Complexes Suitable for Preclinical Development. PLoS ONE, 2016, 11, e0153416.	2.5	40
24	Overexpression of HER-2 in MDA-MB-435/LCC6 Tumours is Associated with Higher Metabolic Activity and Lower Energy Stress. Scientific Reports, 2016, 6, 18537.	3.3	1
25	PRCosomes: pretty reactive complexes formed in liposomes. Journal of Drug Targeting, 2016, 24, 787-796.	4.4	17
26	Synthetic lethality in lung cancer and translation to clinical therapies. Molecular Cancer, 2016, 15, 61.	19.2	31
27	Mastoparan is a membranolytic anti-cancer peptide that works synergistically with gemcitabine in a mouse model of mammary carcinoma. Biochimica Et Biophysica Acta - Biomembranes, 2016, 1858, 3195-3204.	2.6	57
28	Abstract 1319: A novel formulation of CX-5461, a small-molecule inhibitor of rRNA synthesis, and its use for treatment of acute myeloid leukemia models. Cancer Research, 2016, 76, 1319-1319.	0.9	4
29	Abstract 2206: Development and characterization of an injectable copper clioquinol formulation: repurposing of a topical antifungal for treatment of cancer. , 2016, , .		1
30	Abstract 3914: Repurposing disulfiram for use as an anticancer drug: a story about metabolism and metal binding. , 2016, , .		1
31	Combined Use of Gene Expression Modeling and siRNA Screening Identifies Genes and Pathways Which Enhance the Activity of Cisplatin When Added at No Effect Levels to Non-Small Cell Lung Cancer Cells In Vitro. PLoS ONE, 2016, 11, e0150675.	2.5	12
32	Identification of breast cancer cell subtypes sensitive to ATG4B inhibition. Oncotarget, 2016, 7, 66970-66988.	1.8	58
33	Using Pharmacokinetic Profiles and Digital Quantification of Stained Tissue Microarrays as a Medium-Throughput, Quantitative Method for Measuring the Kinetics of Early Signaling Changes Following Integrin-Linked Kinase Inhibition in an In Vivo Model of Cancer. Journal of Histochemistry and Cytochemistry, 2015, 63, 691-709.	2.5	7
34	Irinophore Câ„¢, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer. Journal of Controlled Release, 2015, 199, 72-83.	9.9	19
35	3â€²-Phosphoadenosine 5â€²-phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents. Oncotarget, 2015, 6, 17161-17177.	1.8	17
36	Irinophore Câ„¢, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities. Investigational New Drugs, 2014, 32, 1071-1082.	2.6	14

#	Article	IF	Citations
37	Autophagy Inhibition Augments the Anticancer Effects of Epirubicin Treatment in Anthracycline-Sensitive and -Resistant Triple-Negative Breast Cancer. Clinical Cancer Research, 2014, 20, 3159-3173.	7.0	126
38	Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatments. Nanomedicine, 2014, 9, 501-522.	3.3	9
39	Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer. Investigational New Drugs, 2013, 31, 46-58.	2.6	24
40	Topotecan and Doxorubicin Combination to Treat Recurrent Ovarian Cancer: The Influence of Drug Exposure Time and Delivery Systems to Achieve Optimum Therapeutic Activity. Clinical Cancer Research, 2013, 19, 865-877.	7.0	22
41	Characterization of Long-Circulating Cationic Nanoparticle Formulations Consisting of a Two-Stage PEGylation Step for the Delivery of siRNA in a Breast Cancer Tumor Model. Journal of Pharmaceutical Sciences, 2013, 102, 227-236.	3.3	26
42	Nano-Encapsulation of Arsenic Trioxide Enhances Efficacy against Murine Lymphoma Model while Minimizing Its Impact on Ovarian Reserve In Vitro and In Vivo. PLoS ONE, 2013, 8, e58491.	2.5	63
43	Liposomes. , 2013, , 27-63.		11
44	Combined RNAi-Mediated Suppression of Rictor and EGFR Resulted in Complete Tumor Regression in an Orthotopic Glioblastoma Tumor Model. PLoS ONE, 2013, 8, e59597.	2.5	26
45	Treatment of Colorectal Cancer Using a Combination of Liposomal Irinotecan (Irinophore Câ„¢) and 5-Fluorouracil. PLoS ONE, 2013, 8, e62349.	2.5	24
46	Induction of Autophagy Is an Early Response to Gefitinib and a Potential Therapeutic Target in Breast Cancer. PLoS ONE, 2013, 8, e76503.	2.5	88
47	A novel oral dosage formulation of the ginsenoside aglycone protopanaxadiol exhibits therapeutic activity against a hormone-insensitive model of prostate cancer. Anti-Cancer Drugs, 2012, 23, 543-552.	1.4	31
48	Multivalent rituximab lipid nanoparticles as improved lymphoma therapies: indirect mechanisms of action andin vivoactivity. Nanomedicine, 2011, 6, 1575-1591.	3.3	18
49	Targeting Tumor Hypoxia: Suppression of Breast Tumor Growth and Metastasis by Novel Carbonic Anhydrase IX Inhibitors. Cancer Research, 2011, 71, 3364-3376.	0.9	662
50	Development of a liposomal nanoparticle formulation of 5-Fluorouracil for parenteral administration: Formulation design, pharmacokinetics and efficacy. Journal of Controlled Release, 2011, 150, 212-219.	9.9	62
51	The Role of the Transition Metal Copper and the Ionophore A23187 in the Development of Irinophore Câ„¢. Pharmaceutical Research, 2011, 28, 848-857.	3.5	9
52	Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore Câ„¢), doxorubicin (CaelyxÂ®) or vincristine. BMC Cancer, 2011, 11, 124.	2.6	49
53	The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity. BMC Cancer, 2011, 11, 420.	2.6	25
54	Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor, QLT0267. Cancer Biology and Therapy, 2011, 11, 826-838.	3.4	20

#	Article	IF	Citations
55	A Low Carbohydrate, High Protein Diet Slows Tumor Growth and Prevents Cancer Initiation. Cancer Research, 2011, 71, 4484-4493.	0.9	110
56	Lipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy. Nanomedicine, 2011, 6, 1645-1654.	3.3	4
57	Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles. Journal of Controlled Release, 2010, 144, 332-340.	9.9	78
58	The functional roles of poly(ethylene glycol)â€lipid and lysolipid in the drug retention and release from lysolipidâ€containing thermosensitive liposomes in vitro and in vivo. Journal of Pharmaceutical Sciences, 2010, 99, 2295-2308.	3.3	98
59	Characterization of Cationic Liposome Formulations Designed to Exhibit Extended Plasma Residence Times and Tumor Vasculature Targeting Properties. Journal of Pharmaceutical Sciences, 2010, 99, 2839-2853.	3.3	39
60	Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer. Prostate, 2010, 70, 1437-1447.	2.3	29
61	Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1. Oncogene, 2010, 29, 6343-6356.	5.9	48
62	siRNA-Mediated Integrin-Linked Kinase Suppression: Nonspecific Effects of siRNA/Cationic Liposome Complexes Trigger Changes in the Expression of Phosphorylated-AKT and mTOR Independently of ILK Silencing. Oligonucleotides, 2009, 19, 129-140.	2.7	8
63	Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy. Cancer Chemotherapy and Pharmacology, 2009, 64, 1085-1095.	2.3	44
64	QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model. Breast Cancer Research, 2009, 11, R25.	5.0	60
65	Selective Recognition of Rituximab-Functionalized Gold Nanoparticles by Lymphoma Cells Studied with 3D Imaging. Journal of Physical Chemistry C, 2009, 113, 20252-20258.	3.1	21
66	Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes. International Journal of Pharmaceutics, 2008, 349, 38-46.	5.2	58
67	A novel liposomal irinotecan formulation with significant anti-tumour activity: Use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 68, 607-617.	4.3	46
68	Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-ÎºB, p53, bax, and p27 levels. Molecular Cancer Therapeutics, 2008, 7, 749-758.	4.1	42
69	Rictor and Integrin-Linked Kinase Interact and Regulate Akt Phosphorylation and Cancer Cell Survival. Cancer Research, 2008, 68, 1618-1624.	0.9	200
70	Irinophore C, a Novel Nanoformulation of Irinotecan, Alters Tumor Vascular Function and Enhances the Distribution of 5-Fluorouracil and Doxorubicin. Clinical Cancer Research, 2008, 14, 7260-7271.	7.0	43
71	Irinophore C: A Liposome Formulation of Irinotecan with Substantially Improved Therapeutic Efficacy against a Panel of Human Xenograft Tumors. Clinical Cancer Research, 2008, 14, 1208-1217.	7.0	37
72	Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of Integrin-linked kinase (ILK). Molecular Cancer Therapeutics, 2008, 7, 59-70.	4.1	62

#	Article	IF	Citations
73	A Cationic Liposomal Vincristine Formulation with Improved Vincristine Retention, Extended Circulation Lifetime and Increased Anti-Tumor Activity. Letters in Drug Design and Discovery, 2007, 4, 426-433.	0.7	5
74	Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs. Molecular Cancer Therapeutics, 2007, 6, 844-855.	4.1	54
75	In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 65, 289-299.	4.3	32
76	Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochimica Et Biophysica Acta - Biomembranes, 2007, 1768, 678-687.	2.6	117
77	Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: Relating plasma circulation lifetimes to protein binding. Biochimica Et Biophysica Acta - Biomembranes, 2007, 1768, 1367-1377.	2.6	286
78	Magnetic Resonance Imaging of Temperature-Sensitive Liposome Release: Drug Dose Painting and Antitumor Effects. Journal of the National Cancer Institute, 2007, 99, 53-63.	6.3	254
79	Irinotecanâ€“cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line. Cancer Chemotherapy and Pharmacology, 2007, 60, 91-102.	2.3	12
80	Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin. Breast Cancer Research and Treatment, 2007, 106, 319-331.	2.5	18
81	Liposomal Drug Delivery: Recent Patents and Emerging Opportunities. Recent Patents on Drug Delivery and Formulation, 2007, 1, 185-194.	2.1	16
82	Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Molecular Cancer Therapeutics, 2006, 5, 1854-1863.	4.1	295
83	Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma. Leukemia Research, 2006, 30, 449-457.	0.8	29
84	A Parenteral Econazole Formulation Using a Novel Micelle-to-Liposome Transfer Method: In Vitro Characterization and Tumor Growth Delay in a Breast Cancer Xenograft Model. Pharmaceutical Research, 2006, 23, 2575-2585.	3.5	105
85	Transition Metal-Mediated Liposomal Encapsulation of Irinotecan (CPT-11) Stabilizes the Drug in the Therapeutically Active Lactone Conformation. Pharmaceutical Research, 2006, 23, 2799-2808.	3.5	42
86	Copperâ€“topotecan complexation mediates drug accumulation into liposomes. Journal of Controlled Release, 2006, 114, 78-88.	9.9	65
87	Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magnetic Resonance in Medicine, 2006, 56, 1011-1018.	3.0	119
88	Temporal targeting in cancer: combined chemotherapy and antiangiogenic therapy. Nanomedicine, 2006, 1, 359-363.	3.3	0
89	Gene Silencing in the Development of Personalized Cancer Treatment: The Targets, the Agents and the Delivery Systems. Current Gene Therapy, 2006, 6, 505-533.	2.0	16
90	Development and Assessment of Conventional and Targeted Drug Combinations for Use in the Treatment of Aggressive Breast Cancers. Current Cancer Drug Targets, 2006, 6, 455-489.	1.6	36

#	Article	IF	Citations
91	Preferential Dependence of Breast Cancer Cells versus Normal Cells on Integrin-Linked Kinase for Protein Kinase B/Akt Activation and Cell Survival. Cancer Research, 2006, 66, 393-403.	0.9	113
92	A Parenteral Econazole Formulation Using a Novel Micelle-to-Liposome Transfer Method: In Vitro Characterization and Tumor Growth Delay in a Breast Cancer Xenograft Model. Pharmaceutical Research, 2006, 23, 2575-2585.	3.5	9
93	Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene, 2005, 24, 3596-3605.	5.9	101
94	Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese. Journal of Controlled Release, 2005, 104, 271-288.	9.9	108
95	Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity. Journal of Controlled Release, 2005, 105, 89-105.	9.9	38
96	The Formulation of Lipid-Based Nanotechnologies for the Delivery of Fixed Dose Anticancer Drug Combinations. Current Drug Delivery, 2005, 2, 341-351.	1.6	50
97	Preparation, Characterization, and Biological Analysis of Liposomal Formulations of Vincristine. Methods in Enzymology, 2005, 391, 40-57.	1.0	46
98	The Liposomal Formulation of Doxorubicin. Methods in Enzymology, 2005, 391, 71-97.	1.0	332
99	Cell Based Assays Completed with the Mantle Cell Lymphoma Cell Lines Z138 and NCEB-1 Indicate That Combinations of Bortezomid and Flavopiridol Interact To Achieve Synergistic Activity.. Blood, 2005, 106, 2410-2410.	1.4	2
100	Antitumor Efficacy of Oblimersen Bcl-2 Antisense Oligonucleotide Alone and in Combination with Vinorelbine in Xenograft Models of Human Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2004, 10, 7662-7670.	7.0	33
101	Treatment of HER-2/neu Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/neu and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction. Clinical Cancer Research, 2004, 10, 2512-2524.	7.0	77
102	Pharmacodynamic Behavior of Liposomal Antisense Oligonucleotides Targeting Her-2/neu and Vascular Endothelial Growth Factor in an Ascitic MDA435/LCC6 Human Breast Cancer Model. Cancer Biology and Therapy, 2004, 3, 197-204.	3.4	29
103	In Vitro and in Vivo Characterization of Doxorubicin and Vincristine Coencapsulated within Liposomes through Use of Transition Metal Ion Complexation and pH Gradient Loading. Clinical Cancer Research, 2004, 10, 728-738.	7.0	95
104	Liposomal Irinotecan. Clinical Cancer Research, 2004, 10, 6638-6649.	7.0	75
105	An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes. Journal of Controlled Release, 2004, 96, 449-461.	9.9	94
106	In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: Illustration of targeted delivery. Magnetic Resonance in Medicine, 2004, 51, 1153-1162.	3.0	176
107	pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol. Biochimica Et Biophysica Acta - Biomembranes, 2004, 1661, 47-60.	2.6	86
108	Antennapedia transduction sequence promotes anti tumour immunity to epicutaneously administered CTL epitopes. Vaccine, 2004, 22, 1985-1991.	3.8	43

#	Article	IF	Citations
109	HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization. Molecular Cancer Research, 2004, 2, 606-19.	3.4	11
110	HER-2/neu Overexpression Increases the Viable Hypoxic Cell Population within Solid Tumors without Causing Changes in Tumor Vascularization. Molecular Cancer Research, 2004, 2, 606-619.	3.4	24
111	Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model. Journal of Experimental Therapeutics and Oncology, 2003, 3, 261-271.	0.5	4
112	Targeting of antibody conjugated, phosphatidylserine-containing liposomes to vascular cell adhesion molecule 1 for controlled thrombogenesis. Biochimica Et Biophysica Acta - Biomembranes, 2003, 1613, 115-121.	2.6	32
113	Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Vaccine, 2003, 21, 3319-3329.	3.8	62
114	Prevention of Antibody-Mediated Elimination of Ligand-Targeted Liposomes by Using Poly(Ethylene) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	2.5	35
115	Effects of phosphatidylserine on membrane incorporation and surface protection properties of exchangeable poly(ethylene glycol)-conjugated lipids. Biochimica Et Biophysica Acta - Biomembranes, 2002, 1560, 37-50.	2.6	27
116	Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes. Biochimica Et Biophysica Acta - Biomembranes, 2002, 1561, 188-201.	2.6	60
117	Formation of transition metalâ€“doxorubicin complexes inside liposomes. Biochimica Et Biophysica Acta - Biomembranes, 2002, 1565, 41-54.	2.6	150
118	Attaching histidine-tagged peptides and proteins to lipid-based carriers through use of metal-ion-chelating lipids. Biochimica Et Biophysica Acta - Biomembranes, 2002, 1567, 204-212.	2.6	57
119	Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human melanoma cells. International Journal of Pharmaceutics, 2002, 241, 57-64.	5.2	12
120	A Comparison of Liposomal Formulations of Doxorubicin with Drug Administered in Free Form. Drug Safety, 2001, 24, 903-920.	3.2	183
121	Oxazole yellow homodimer YOYO-1-labeled DNA: a fluorescent complex that can be used to assess structural changes in DNA following formation and cellular delivery of cationic lipid DNA complexes. Biochimica Et Biophysica Acta - General Subjects, 2001, 1527, 61-72.	2.4	22
122	Selective protein interactions with phosphatidylserine containing liposomes alter the steric stabilization properties of poly(ethylene glycol). Biochimica Et Biophysica Acta - Biomembranes, 2001, 1510, 56-69.	2.6	52
123	Surface-associated serum proteins inhibit the uptake of phosphatidylserine and poly(ethylene glycol) liposomes by mouse macrophages. Biochimica Et Biophysica Acta - Biomembranes, 2001, 1513, 25-37.	2.6	114
124	Intermembrane transfer of polyethylene glycol-modified phosphatidylethanolamine as a means to reveal surface-associated binding ligands on liposomes. Biochimica Et Biophysica Acta - Biomembranes, 2001, 1513, 193-206.	2.6	35
125	Drug-drug interactions arising from the use of liposomal vincristine in combination with other anticancer drugs. Pharmaceutical Research, 2001, 18, 1331-1335.	3.5	8
126	Characterization of hybrid CTL epitope delivery systems consisting of the Antennapedia homeodomain peptide vector formulated in liposomes. Journal of Immunological Methods, 2001, 254, 119-135.	1.4	16

#	Article	IF	Citations
127	Efficient Delivery of Antennapedia Homeodomain Fused to CTL Epitope with Liposomes into Dendritic Cells Results in the Activation of CD8+ T Cells. Journal of Immunology, 2001, 167, 6462-6470.	0.8	56
128	Use of Poly(ethylene glycol)â€“Lipid Conjugates to Regulate the Surface Attributes and Transfection Activity of Lipidâ€“DNA Particles. , 2000, 89, 652-663.		141
129	Designing Liposomal Anticancer Drug Formulations for Specific Therapeutic Applications. Journal of Liposome Research, 2000, 10, 99-115.	3.3	27
130	Antibody Conjugation Methods for Active Targeting of Liposomes. , 2000, 25, 51-68.		20
131	Targeted Gene Transfer: A Practical Guide Based on Experience with Lipid-Based Plasmid Delivery Systems. , 2000, 25, 255-304.		1
132	Clinical and Preclinical Pharmacology of Liposomal Vincristine. Journal of Liposome Research, 2000, 10, 501-512.	3.3	4
133	Use of poly(ethylene glycol)â€“lipid conjugates to regulate the surface attributes and transfection activity of lipidâ€“DNA particles. Journal of Pharmaceutical Sciences, 2000, 89, 652.	3.3	95
134	Liposomal Anticancer Drugs as Agents to be used in Combination with other Anticancer Agents: Studies on a Liposomal Formulation with two Encapsulated Drugs. Journal of Liposome Research, 1999, 9, 507-522.	3.3	11
135	Intravenous Pretreatment with Empty pH Gradient Liposomes Alters the Pharmacokinetics and Toxicity of Doxorubicin through In Vivo Active Drug Encapsulation. Journal of Pharmaceutical Sciences, 1999, 88, 96-102.	3.3	31
136	Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity. Nature Biotechnology, 1999, 17, 775-779.	17.5	117
137	Biological barriers to cellular delivery of lipid-based DNA carriers. Advanced Drug Delivery Reviews, 1999, 38, 291-315.	13.7	168
138	A multi-step lipid mixing assay to model structural changes in cationic lipoplexes used for in vitro transfection. Biochimica Et Biophysica Acta - Biomembranes, 1999, 1461, 27-46.	2.6	39
139	Electrostatically Mediated Interactions between Cationic Lipidâ€“DNA Particles and an Anionic Surface. Archives of Biochemistry and Biophysics, 1999, 366, 31-39.	3.0	8
140	Cationic Liposomeâ€“Plasmid DNA Complexes Used for Gene Transfer Retain a Significant Trapped Volume. Journal of Pharmaceutical Sciences, 1998, 87, 9-14.	3.3	14
141	Clearance properties of liposomes involving conjugated proteins for targeting. Advanced Drug Delivery Reviews, 1998, 32, 99-118.	13.7	48
142	Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. Cancer Chemotherapy and Pharmacology, 1998, 41, 347-352.	2.3	48
143	Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemotherapy and Pharmacology, 1998, 42, 461-470.	2.3	66
144	Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. Biochimica Et Biophysica Acta - Biomembranes, 1998, 1372, 272-282.	2.6	144

#	Article	IF	Citations
145	Characterization of Lipid DNA Interactions. I. Destabilization of Bound Lipids and DNA Dissociation. Biophysical Journal, 1998, 75, 1040-1051.	0.5	84
146	Controlling the Drug Delivery Attributes of Lipid-Based Drug Formulations. Journal of Liposome Research, 1998, 8, 299-335.	3.3	34
147	Liposomal Vincristine: The Central Role of Drug Retention in Defining Therapeutically Optimized Anticancer Formulations. , 1998, , 29-49.		8
148	Human gene therapy: principles and modern advances. Biotechnology Annual Review, 1997, 3, 59-110.	2.1	1
149	Analysis of Cationic Liposome-mediated Interactions of Plasmid DNA with Murine and Human Melanoma Cells in Vitro. Journal of Biological Chemistry, 1997, 272, 19480-19487.	3.4	31
150	Liposome Targeting Following Intravenous Administration: Defining Expectations and a Need for Improved Methodology. Journal of Liposome Research, 1997, 7, 331-361.	3.3	10
151	Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. BBA - Biomembranes, 1997, 1331, 187-211.	8.0	185
152	An immune response to ovalbumin covalently coupled to liposomes is prevented when the liposomes used contain doxorubicin. Journal of Immunological Methods, 1997, 210, 137-148.	1.4	24
153	Lipid/DNA complexes as an intermediate in the preparation of particles for gene transfer: an alternative to cationic liposome/DNA aggregates. Advanced Drug Delivery Reviews, 1997, 24, 275-290.	13.7	30
154	Self-assembling DNA-lipid particles for gene transfer. Pharmaceutical Research, 1997, 14, 190-196.	3.5	56
155	Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes. Cancer Chemotherapy and Pharmacology, 1997, 40, 309-317.	2.3	47
156	Validation of a high-performance liquid chromatographic assay method for quantification of total vincristine sulfate in human plasma following administration of vincristine sulfate liposome injection. Journal of Pharmaceutical and Biomedical Analysis, 1997, 16, 675-687.	2.8	32
157	Genetic allogenization of malignant melanoma. Transfusion Science, 1996, 17, 169-174.	0.6	5
158	Cationic Lipid Binding to DNA:Â Characterization of Complex Formationâ€. Biochemistry, 1996, 35, 5756-5763.	2.5	115
159	Vincristine-induced dermal toxicity is significantly reduced when the drug is given in liposomes. Cancer Chemotherapy and Pharmacology, 1996, 37, 351-355.	2.3	39
160	Plasmid DNA is Protected against Ultrasonic Cavitation-Induced Damage when Complexed to Cationic Liposomes. Journal of Pharmaceutical Sciences, 1996, 85, 427-433.	3.3	70
161	LIPOSOMAL CYCLOSPORINE. Transplantation, 1995, 60, 1006.	1.0	18
162	Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. British Journal of Cancer, 1995, 72, 896-904.	6.4	214

#	Article	IF	Citations
163	A model approach for assessing liposome targetingin vivo. Drug Delivery, 1995, 2, 156-165.	5.7	6
164	Encapsulation of Vincristine in Liposomes Reduces its Toxicity and Improves its Anti-Tumor Efficacy. Journal of Liposome Research, 1995, 5, 523-541.	3.3	58
165	Poly(ethylene glycol)-Modified Phospholipids Prevent Aggregation during Covalent Conjugation of Proteins to Liposomes. Bioconjugate Chemistry, 1995, 6, 187-194.	3.6	58
166	The cationic lipid stearylamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: Implications for drug delivery. Biochimica Et Biophysica Acta - Biomembranes, 1995, 1238, 147-155.	2.6	41
167	Formation of Novel Hydrophobic Complexes between Cationic Lipids and Plasmid DNA. Biochemistry, 1995, 34, 12877-12883.	2.5	124
168	A two-step targeting approach for delivery of doxorubicin-loaded liposomes to tumour cells in vivo. Cancer Chemotherapy and Pharmacology, 1995, 36, 91-101.	2.3	30
169	The Use of Transmembrane pH Gradient-Driven Drug Encapsulation in the Pharmacodynamic Evaluation of Liposomal Doxorubicin. Journal of Liposome Research, 1994, 4, 529-553.	3.3	35
170	Polyethylene Glycol Modified Phospholipids Stabilize Emulsions Prepared from Triacylglycerol â€. Journal of Pharmaceutical Sciences, 1994, 83, 1558-1564.	3.3	60
171	Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice. Cancer Chemotherapy and Pharmacology, 1994, 34, 137-146.	2.3	53
172	Liposome encapsulated vincristine: preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogs. Anti-Cancer Drugs, 1994, 5, 579-590.	1.4	50
173	The presence of GM1 in liposomes with entrapped doxorubicin does not prevent RES blockade. Lipids and Lipid Metabolism, 1993, 1168, 249-252.	2.6	23
174	Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemotherapy and Pharmacology, 1993, 33, 17-24.	2.3	77
175	Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes. Cancer Chemotherapy and Pharmacology, 1990, 27, 13-19.	2.3	65
176	The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chemistry and Physics of Lipids, 1990, 53, 37-46.	3.2	231
177	Liposomes with entrapped doxorubicin exhibit extended blood residence times. Biochimica Et Biophysica Acta - Biomembranes, 1990, 1023, 133-139.	2.6	95
178	Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochimica Et Biophysica Acta - Biomembranes, 1990, 1025, 143-151.	2.6	216
179	Dopamine accumulation in large unilamellar vesicle systems induced by transmembrane ion gradients. Chemistry and Physics of Lipids, 1988, 47, 97-107.	3.2	43
180	A non-covalent method of attaching antibodies to liposomes. Biochimica Et Biophysica Acta - Biomembranes, 1987, 901, 157-160.	2.6	63

#	Article	IF	Citations
181	Techniques for encapsulating bioactive agents into liposomes. Chemistry and Physics of Lipids, 1986, 40, 333-345.	3.2	158
182	Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochimica Et Biophysica Acta - Biomembranes, 1985, 816, 294-302.	2.6	139